Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBPK-Guided Optimization of Linezolid Dosing for Neonatal Sepsis
ChiCTR2200063104Phase 4Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of linezolid in neonatal sepsis and neonatal infection (2 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: Serum linezolid concentration and Serum linezolid metabolite concentrations. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
linezolid
03
Conditions
neonatal sepsisneonatal infection
Beyond the preview
Go deeper on ChiCTR2200063104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063104.